Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,643Revenue (TTM) $M5,957Net Margin (%)14.3Altman Z-Score1.7
Enterprise Value $M13,048EPS (TTM) $0.9Operating Margin %14.6Piotroski F-Score4
P/E(ttm)9.3Beneish M-Score--Pre-tax Margin (%)19.4Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %13.7Quick Ratio0.7Cash flow > EarningsN
Price/Sales1.35-y EBITDA Growth Rate %-4.1Current Ratio1.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %-36.9ROA % (ttm)4.1Higher Current Ratio y-yY
Dividend Yield %5.3PEG--ROE % (ttm)10.8Less Shares Outstanding y-yY
Payout Ratio %52.0Shares Outstanding M908ROIC % (ttm)5.3Gross Margin Increase y-yY

Gurus Latest Trades with OTCPK:KPELY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KPELYDavid Dreman 2014-09-30 Sold Out $16.425 - $17.815
($17.3)
$ 8.42-51%Sold Out0
KPELYDavid Dreman 2014-06-30 Buy $16.53 - $18.04
($17.12)
$ 8.42-51%New holding1,113
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OTCPK:KPELY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


OTCPK:KPELY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about OTCPK:KPELY:

    News about OTCPK:KPELY:

    Articles On GuruFocus.com
    Smith & Wesson Reports Strong Quarter, but Stock Suffers Post Election Dec 02 2016 
    6 Things That May Surprise You About Building Wealth Dec 02 2016 
    Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals Dec 02 2016 
    Thoughts on the Election Dec 02 2016 
    Foot Locker Is Doing Great Dec 02 2016 
    Aussie Recovery Subdued as Traders Wait for Short Entries Dec 02 2016 
    US Market Indexes Mixed on Thursday Dec 02 2016 
    FDA Orphan Drug Designation for AbbVie's Risankizumab Dec 01 2016 
    Titlis AG Has Been Growing With Swiss Skiing Dec 01 2016 
    Innovating to Protect and Grow Its Dividend Dec 01 2016 

    More From Other Websites
    No related articles found.

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK